| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,456,282 | -7,508,117 |
| Stock based compensation | 864,031 | 681,843 |
| Amortization of intangibles | 75,000 | 50,000 |
| Realized and unrealized gain and accrued interest on investments | 138,811 | 140,996 |
| Increase (decrease) in accounts payable and accrued expenses | 1,583,619 | 156,567 |
| Decrease in prepaid expenses and other assets | -566,474 | -480,193 |
| Net cash used in operating activities | -8,505,969 | -6,280,510 |
| Proceeds from redemption of investments | 6,990,574 | 4,452,701 |
| Net cash provided by investing activities | 6,990,574 | 4,452,701 |
| Payment of amounts due to officers | 450,000 | 300,000 |
| Proceeds from sale of equity securities, net | 172,958 | 172,958 |
| Net cash (used in) provided by financing activities | -277,042 | -127,042 |
| Net change in cash and cash equivalents | -1,792,437 | -1,954,851 |
| Cash and cash equivalents at beginning of period | 3,623,343 | - |
| Cash and cash equivalents at end of period | 1,830,906 | - |
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)